PHASE-II STUDY OF ALPHA-INTERFERON AND 13-CIS-RETINOIC ACID IN METASTATIC MELANOMA
PHASE-II STUDY OF ALPHA-INTERFERON AND 13-CIS-RETINOIC ACID IN METASTATIC MELANOMA
复制标题
DOI：
10.1007/bf00873908
复制
发表时间：
1993-02-01
影响因子：
3.4
通讯作者：
LEGHA, SS
中科院分区：
文献类型：
--
作者：
DHINGRA, K;PAPADOPOULOS, N;LEGHA, SS
α -干扰素和13-顺式维甲酸的组合已显示出对许多人类肿瘤的显著活性。我们进行了一项II期试验，以测试该联合疗法对难治性转移性黑色素瘤患者的主要缓解率是否达到30%或更高。11名患者接受了这项研究。α -干扰素每周皮下注射3次，剂量为1000万U/m2, 13-顺式维甲酸口服剂量为1mg /kg/天。没有患者达到部分或完全缓解。α -干扰素和13-顺式维甲酸联合使用不太可能比α -干扰素单独使用有更高的治疗活性。
The combination of alpha-interferon and 13-cis-retinoic acid has shown significant activity against a number of human tumors. We conducted a phase II trial to test whether the combination would have a major response rate of 30% or more in patients with refractory, metastatic melanoma. Eleven patients were treated on the study. Alpha-interferon was administered subcutaneously three times a week at a dose of 10 million U/m2 and 13-cis-retinoic acid was administered orally at a dose of 1 mg/kg/day. No patient achieved a partial or complete remission. The combination of alpha-interferon and 13-cis-retinoic acid is unlikely to have significantly higher therapeutic activity than alpha-interferon alone.